7 completed. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 2 | Completed 2 |
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis MaaT033 - Amyotrophic Lateral Sclerosis, ALS | Phase 1 | Completed | MaaT Pharma | 15 | 2023-06-08 | 2025-06-15 |
| Trial of Oxaloacetate in ALS Oxaloacetic Acid - ALS | Phase 1 | Completed | Omar Jawdat | 18 | 2020-03-17 | 2024-06-06 |
| A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) Triheptanoin - ALS | Phase 1 / Phase 2 | Completed | Richard Bedlack, M.D., Ph.D. | 15 | 2018-06-21 | 2019-12-24 |
| Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS BHV-0223 - Amyotrophic Lateral Sclerosis, ALS | Phase 1 | Completed | Biohaven Pharmaceuticals, Inc. | 22 | 2018-02-02 | 2022-10-06 |
| A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS) RNS60 - ALS | Phase 1 | Completed | Sabrina Paganoni, M.D. | 24 | 2015-10-01 | 2021-05-28 |
| Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis HYNR-CS inj, Control group - Amyotrophic Lateral Sclerosis, ALS | Phase 1 / Phase 2 | Completed | Corestemchemon, Inc. | 72 | 2011-02-01 | 2022-03-17 |
| Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis Tongue Piercing, Usability assessment - Quadriplegia, Spinal Cord Injury | Phase 1 | Completed | Georgia Institute of Technology | 61 | 2010-05-01 | 2013-09-18 |
Amyotrophic Lateral Sclerosis (3) · Motor Neuron Disease (1) · Neurodegenerative Diseases (1) · Paralysis (1) · Quadriplegia (1) · Spinal Cord Injuries (1)
Central Nervous System Diseases (4) · Nervous System Diseases (4) · Spinal Cord Diseases (4) · Metabolic Diseases (3) · Neuromuscular Diseases (3) · Nutritional and Metabolic Diseases (3) · Proteostasis Deficiencies (3) · TDP-43 Proteinopathies (3) · Motor Neuron Disease (2) · Neurodegenerative Diseases (2) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Trauma, Nervous System (1) · Wounds and Injuries (1)
Body Piercing (1) · Control Groups (1) · Oxaloacetic Acid (1) · Oxygen (1) · RNS60 (1) · Sodium Chloride (1) · triheptanoin (1)
Biohaven Pharmaceuticals, Inc. (1) · Corestemchemon, Inc. (1) · Georgia Institute of Technology (1) · MaaT Pharma (1) · Omar Jawdat (1) · Richard Bedlack, M.D., Ph.D. (1) · Sabrina Paganoni, M.D. (1)
United States (5) · France (1) · South Korea (1)
Gaelle Bruneteau, MD, PhD (1) · Maysam Ghovanloo, Ph.D. (1) · Nazem Atassi, MD (1) · Omar Jawdat, MD (1) · Richard S Bedlack, MD PhD (1) · Sabrina Paganoni, MD (1) · Seung Hyun Kim, M.D., Ph.D. (1)
PMID 21652288, PMID 22531737, PMID 22692932, PMID 24284925, PMID 25934946, PMID 30048006
1RC1EB010915-01 (1)